Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials

Aspirin and Preeclampsia

NCT04479072
Recruiting
Conditions Preeclampsia Postpartum
Phase PHASE4
Enrollment 180
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

This is a single-center, double-blind, randomized, placebo-controlled clinical trial. Peripartum and postpartum Activin A are significantly elevated in women with preeclampsia. Our hypothesis is that elevated Activin A levels reflect a remediable signal and that reducing postpartum Activin A levels with aspirin therapy will improve (GLS) in preeclamptic patients.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Factorial Primary purpose: Prevention Masking/blinding: Double

Interventions / Regimen

  • Drug: Aspirin 81 mg — Subjects in the interventional arm will receive a daily dose of aspirin 81 mg, starting at their baseline visit and to be taken up to their 6-month follow-up visit.
  • Drug: Placebo — Subjects in this group will receive a daily dose of a placebo pill, starting at their baseline visit and to be taken up to their 6-month follow-up visit.

Primary Outcomes

  • Difference in Activin A levels (6 Months)
  • GLS percentages (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2021-02-15
Completion: 2026-12-31
Eligibility
Age: 18 Years – 45 Years
Sex: FEMALE
Volunteers: false
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Chicago
Contact Information
Study Contact:
Sajid Shahul, MD, PhD
773-398-2956
sshahul1@dacc.uchicago.edu
Colleen Duncan, RN
7738342892
cduncan@bsd.uchicago.edu
Sajid Shahul, MD, PhD
773-398-2956
sshahul1@dacc.uchicago.edu
University of Chicago Hospital
Interventions
  • Drug: Aspirin 81 mg — Subjects in the interventional arm will receive a daily dose of aspirin 81 mg, starting at their baseline visit and to be taken up to their 6-month follow-up visit.
  • Drug: Placebo — Subjects in this group will receive a daily dose of a placebo pill, starting at their baseline visit and to be taken up to their 6-month follow-up visit.
Study Locations (1 sites)
University of Chicago Hospital, Chicago, Illinois 60637 United States
Eligibility Criteria
Inclusion Criteria: 1. Pregnant Adults between 18 and 45 years of age 2. Diagnosed with preeclampsia 3. Presenting for delivery with a singleton gestation. Exclusion Criteria: 1. We will exclude patients in labor 2. Patients with preexisting cardiomyopathy, chronic hypertension, ischemic or valvular heart disease, pulmonary disease, diabetes mellitus, chronic kidney disease, multiple gestation 3. Plan to deliver outside of the participating site 4. Co-enrolled in other trials that might affect the patients taking the study medication, as determined by the PI. 5. Aspirin allergy 6. Clear indication for aspirin therapy or contraindication to aspirin therapy 7. Clinically significant conditions that might limit adherence to trial regimen (e.g., peptic ulcer disease, history of gastrointestinal bleeds, bleeding disorders) 8. Currently or planning on taking any nonsteroidal anti-inflammatory drugs while they are participating in this study. 9. Those who cannot provide consent
Conditions Pulmonary Arterial Hypertension
Phase PHASE2
Enrollment 6
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to learn about the safety of sotatercept and how well Japanese children tolerate it, when taken along with standard (usual) pulmonary arterial hypertension (PAH) treatment. Researchers also want to learn what happens to it in a person's body over time and whether it lowers resistance in blood vessels in the lungs.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: Sotatercept — Sotatercept subcutaneous injection every 3 weeks

Primary Outcomes

  • Number of Participants With One or More Adverse Events (Up to approximately 24 weeks)
  • Number of Participants Who Discontinue Study Intervention Due to an Adverse Event (Up to approximately 24 weeks)
  • Laboratory Parameter (Hematology): Concentration of Hemoglobin (Up to approximately 24 weeks)
  • Laboratory Parameter (Hematology): Hematocrit (Up to approximately 24 weeks)
  • Laboratory Parameter (Hematology): Red Blood Cell (RBC) Count (Up to approximately 24 weeks)
  • Laboratory Parameter (Hematology): Reticulocyte Count (Up to approximately 24 weeks)
  • Laboratory Parameter (Hematology): Platelet Count (Up to approximately 24 weeks)
  • Blood Pressure (BP) (Up to approximately 24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-09-17
Completion: 2031-05-16
Eligibility
Age: 1 Year – 17 Years
Sex: ALL
Volunteers: false
Enrollment: 6 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Merck Sharp & Dohme LLC
Principal Investigators:
  • Medical Director (STUDY_DIRECTOR) - Merck Sharp & Dohme LLC
Contact Information
Study Contact:
Toll Free Number
1-888-577-8839
Trialsites@msd.com
Study Coordinator
+81-725-56-1260
Osaka Prefectural Hospital Organization Osaka Women's and Children's Hospital ( Site 3203)
Study Coordinator
+81-6-6879-5111
The University of Osaka Hospital ( Site 3201)
Interventions
  • Biological: Sotatercept — Sotatercept subcutaneous injection every 3 weeks
Study Locations (3 sites)
Osaka Prefectural Hospital Organization Osaka Women's and Children's Hospital ( Site 3203), Izumi, Osaka 594-1101 Japan
The University of Osaka Hospital ( Site 3201), Suita, Osaka 565-0871 Japan
National Center for Child Health and Development ( Site 3202), Setagaya City, Tokyo 157-8535 Japan
Eligibility Criteria
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has pulmonary arterial hypertension (PAH, World Health Organization Group 1) confirmed by a prior right heart catheterization * Has idiopathic, heritable, drug- or toxin-induced PAH, connective tissue disease-associated PAH, repaired congenital heart disease-associated PAH, or PAH with coincidental shunt * Has PAH classified as World Health Organization Functional Class I, or symptomatic World Health Organization Functional Class II to IV * Has been receiving stable standard-of-care background therapy for PAH for at least 90 days * Is Japanese Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * History of left-sided heart disease * Has severe congenital or developmental abnormalities of the lung, thorax, and/or diaphragm * History of Eisenmenger syndrome, Potts shunt, or recent atrial septostomy within 180 days * Has unrepaired or residual cardiac shunt with Qp/Qs \>1.5 * Has pulmonary veno-occlusive disease, pulmonary capillary hemangiomatosis, or overt signs of pulmonary capillary and/or venous involvement * PAH associated with portal hypertension * Known visceral arteriovenous malformations * History of full or partial pneumonectomy * Untreated more than mild obstructive sleep apnea * History of known pericardial constriction * Family history of sudden cardiac death or long QT syndrome * History of symptomatic coronary disease within 6 months or cerebrovascular accident within 3 months * Prior treatment with sotatercept or luspatercept
Conditions Cataract, Glaucoma, Ocular Hypertension
Phase PHASE3
Enrollment 400
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

This trial is a randomized study to evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Bimatoprost Implant System — Bimatoprost Implant System used in combination with the SpyGlass IOL
  • Device: SpyGlass IOL — SpyGlass Intraocular Lens
  • Drug: Timolol Maleate Ophthalmic Solution, 0.5% — Timolol Maleate Ophthalmic Solution, 0.5% BID
  • Device: Commercial IOL — Commercially Available Aspheric Monofocal Non-Yellow Chromophore Intraocular Lens

Primary Outcomes

  • Mean IOP Reduction from Baseline (mmHg) (Weeks 2 and 6, and Month 3)
  • BCDVA 20/40 or better (Month 6)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-10-28
Completion: 2031-05-31
Eligibility
Age: 22 Years and older
Sex: ALL
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: SpyGlass Pharma, Inc.
Principal Investigators:
  • Paul Yoo, OD (STUDY_CHAIR) - SpyGlass Pharma
Contact Information
Study Contact:
Director, Clinical Affairs
949-284-6904
clinical@spyglasspharma.com
Clinical Research Coordinator
2104242584
maggie@eye-assoc.com
R and R Eye Research, LLC
Interventions
  • Drug: Bimatoprost Implant System — Bimatoprost Implant System used in combination with the SpyGlass IOL
  • Device: SpyGlass IOL — SpyGlass Intraocular Lens
  • Drug: Timolol Maleate Ophthalmic Solution, 0.5% — Timolol Maleate Ophthalmic Solution, 0.5% BID
  • Device: Commercial IOL — Commercially Available Aspheric Monofocal Non-Yellow Chromophore Intraocular Lens
Study Locations (1 sites)
R and R Eye Research, LLC, San Antonio, Texas 78229 United States
Eligibility Criteria
Inclusion Criteria: * Diagnosis of mild to moderate open-angle glaucoma or ocular hypertension * Planned removal of cataract * Female participants of childbearing potential must have a negative urine pregnancy test at the baseline visit and agree to the use of contraception Exclusion Criteria: * Uncontrolled systemic disease * History of incisional/refractive corneal surgery * Any glaucoma diagnosis other than OHT, open-angle, pseudoexfoliative, or pigmentary glaucoma * History of incisional glaucoma surgery or intraocular injections * Other ocular diseases, pathology, or conditions
Conditions Elevated LDL-C and High Cholesterol
Phase PHASE1
Enrollment 64
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

STX-1150 is an investigational therapy designed to lower LDL-C by silencing a gene called PCSK9 in the liver. STX-1150 does not edit or permanently change the gene. STX-1150 comprises an mRNA and guide RNA (gRNA) delivered via lipid nanoparticles (LNP) for intravenous infusion. The mRNA produces a protein that switches off the PCSK9 gene expression without altering the DNA sequence. This process leverages natural mechanisms that regulate gene activity. The study will enroll up to 64 participants with elevated LDL-C across sites in Australia and New Zealand. The follow-up period will be up to 1- year post-treatment.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: STX-1150 — Drug: STX-1150 is an investigational product designed to epigenetically silence the PCSK9 gene. Epigenome modulation offers a way to silence genes without changing their underlying DNA sequence.

Primary Outcomes

  • Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs) (Up to Week 52 from administration of STX-1150)
  • Incidence and Severity of Serious Adverse Events (SAEs) (Up to Week 52 from administration of STX-1150)
  • Incidence and Severity of Adverse Events of Special Interest (AESI) (Up to Week 52 from administration of STX-1150)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-06-30
Completion: 2028-12-30
Eligibility
Age: 18 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 64 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Monash University
Collaborators: Scribe Therapeutics Inc.
Principal Investigators:
  • Stephen Nicholls, MBBS, FRACP, PhD (STUDY_CHAIR) - VHI
Contact Information
Study Contact:
Domenic Sacca
+61 423245187
domenic.sacca@monash.edu
Raeda Mustafa
+61 477581540
raeda.mustafa@monash.edu
Debra O'Leary, PhD
+61 3 7511 1252
Debra.OLeary@monashhealth.org
Monash Health/ Victorian Heart Hospital (VHH)
Interventions
  • Drug: STX-1150 — Drug: STX-1150 is an investigational product designed to epigenetically silence the PCSK9 gene. Epigenome modulation offers a way to silence genes without changing their underlying DNA sequence.
Study Locations (3 sites)
Monash Health/ Victorian Heart Hospital (VHH), Clayton, Victoria 3168 Australia
Aotearoa Clinical Trials/Middlemore Hospital, Papatoetoe, Auckland 2025 New Zealand
New Zealand Clinical Research (NZCR), Christchurch, Christchurch 8011 New Zealand
Eligibility Criteria
Inclusion Criteria: * Elevated serum LDL-C with or without LDL-C lowering medication * Willing and able to give informed consent before initiation of any study-related procedures and willing to comply with all required study procedures Exclusion Criteria: * Patients with history of an ASCVD event \</= 6 months. * Any uncontrolled or serious disease, or any medical or surgical condition that may interfere with participation * Diagnosis of familial hypercholesterolemia * Active or history of liver disease * Previous treatment with PCSK9-inhibitor or other prior treatment within a specified timeframe * Clinically significant abnormal laboratory values
Conditions Hypertension, MTHFR 677 TT Genotype
Phase PHASE4
Enrollment 24000
Locations 20 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

This is a multi-center, randomized, double-blind, triple-dummy, controlled trial in 24,000 Chinese men and women with hypertension and MTHFR 677 TT genotype. The study participants will be randomized to one of the three treatment groups: Group A: amlodipine tablet (5mg), taken orally, once daily, serving as active comparator. Group B: amlodipine folic acid 5.8mg tablet (5mg amlodipine and 0.8mg folic acid), taken orally, once daily. Group C: amlodipine folic acid 5.8mg tablet plus 5-methyltetrahydrofolate (5-MTHF, 0.4mg), taken orally, once daily. The primary endpoint is first ischemic stroke.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Amlodipine besylate — The amlodipine used in this study is a listed product.
  • Drug: Amlodipine besylate And Folic Acid — The amlodipine besylate and folic acid tablets have been approved for listing by the China Food and Drug Administration, approval number: Zhunzi H20180020.
  • Drug: 5-methyltetrahydrofolate (5-MTHF) — The 5-MTHF used in this study is a listed product.
  • Drug: Amlodipine placebo — Amlodipine placebos are dummy pills of amlodipine with identical appearance.
  • Drug: Amlodipine folic acid placebo — Amlodipine folic acid placebos are dummy pills of amlodipine folic acid with identical appearance.
  • Drug: 5-MTHF Placebos — 5-MTHF placebos are the dummy pills of 5-MTHF with identical appearance.

Primary Outcomes

  • First ischemic stroke (By the end of the fifth year of the study)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2024-08-22
Completion: 2029-06-30
Eligibility
Age: 45 Years – 74 Years
Sex: ALL
Volunteers: false
Enrollment: 24000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shenzhen Ausa Pharmed Co.,Ltd
Collaborators: Peking University First Hospital, Second Affiliated Hospital of Nanchang University, The First People's Hospital of Lianyungang, The Affiliated Hospital Of Guizhou Medical University, Lianyungang Oriental Hospital, Tengzhou Central People's Hospital, The First Affiliated Hospital of Bengbu Medical University, Shenzhen Prospective Medical Technology Co., LTD, Weinan Central Hospital, The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Loudi Central Hospital, Yancheng First People's Hospital, TAIHE country people's hospital, First Affiliated Hospital of Gannan Medical University, Yangjiang People's Hospital, Deyang People's Hospital, Bozhou people's hospital, Chizhou people's hospital, Lianyungang Second People's Hospital, The Affiliated Hospital Of Southwest Medical University, Chengdu Fifth People's Hospital
Principal Investigators:
  • Jianping Li, MD, PhD (PRINCIPAL_INVESTIGATOR) - Peking University First Hospital
Contact Information
Study Contact:
Minqing Tian, PhD
86-18818680849
tianminqing@163.com
Hongju Wang, MD
13955231336
1649134019@qq.com
First Affillated Hospital of Bengbu Medical University
Hongju Wang, MD
First Affillated Hospital of Bengbu Medical University
Interventions
  • Drug: Amlodipine besylate — The amlodipine used in this study is a listed product.
  • Drug: Amlodipine besylate And Folic Acid — The amlodipine besylate and folic acid tablets have been approved for listing by the China Food and Drug Administration, approval number: Zhunzi H20180020.
  • Drug: 5-methyltetrahydrofolate (5-MTHF) — The 5-MTHF used in this study is a listed product.
  • Drug: Amlodipine placebo — Amlodipine placebos are dummy pills of amlodipine with identical appearance.
  • Drug: Amlodipine folic acid placebo — Amlodipine folic acid placebos are dummy pills of amlodipine folic acid with identical appearance.
Study Locations (20 sites)
First Affillated Hospital of Bengbu Medical University, Bengbu, Anhui 233004 China
Bozhou People's Hospital, Bozhou, Anhui China
Chizhou People's Hospital, Chizhou, Anhui China
Taihe County People's Hospital, Fuyang, Anhui China
Peking University First Hospital, Beijing, Beijing Municipality China
Yangjiang People's Hospital, Yangjiang, Guangdong China
The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou China
The First Affiliated Hospital of Hunan University of Medicine, Huaihua, Hunan China
Loudi Central Hospital, Loudi, Hunan China
Lianyungang Oriental Hospital, Lianyungang, Jiangsu 222042 China
Eligibility Criteria
Inclusion Criteria: 1. Men and women, aged ≥45 and \<75 years. 2. Hypertension: Previously diagnosed with primary hypertension and has been taking antihypertensive medication within the past two weeks; OR has not been taking antihypertensive medications within the last two weeks, but meets the following criteria for hypertension: SBP≥140 mmHg and/or DBP≥90 mmHg (average of at least 2 measurements each time) at two separate (not on the same day) clinical visits. 3. MTHFR 677 TT genotype (based on the test results from the central laboratory during the screening period or a previous official test report from a laboratory with medical testing qualifications). 4. Voluntarily participates and has given signed informed consent. Randomized-treatment phase inclusion criteria: 1. Good compliance during the run-in period, and unlikely to discontinue treatment; 2. No stroke or cardiovascular events during the run-in period; 3. The participant voluntarily agrees to continue the study. Exclusion Criteria: 1. Previously diagnosed secondary hypertension; 2. Previously diagnosed stroke; 3. Previously diagnosed myocardial infarction; 4. Previously diagnosed heart failure; 5. Previously diagnosed atrial fibrillation; 6. Cardio-cerebral-kidney revascularization and/or other large arterial stent; 7. Currently on dialysis, or diagnosed with stage 4-5 chronic kidney disease, or eGFR \<30 mL/ min/1.73m²; 8. Known to have congenital (such as aortic stenosis) or acquired organic heart disease; 9. Known to have any of the following severe diseases or conditions: 1. Digestive system: i. Previously diagnosed with any form of viral hepatitis that is currently still in the active phase; ii. Abnormal liver function test before enrollment (any of ALT, AST, GGT, TBIL, DBIL test 3 times higher than normal, or ALB≤30g/L); iii. Subtotal gastrectomy and/or gastrojejunostomy; 2. Respiratory system: previously diagnosed with pulmonary heart disease; 3. Presence of malignant tumors or other severe diseases; 4. Presence of long-term gastrointestinal symptoms such as ; anorexia, decreased appetite, nausea, and abdominal bloating; 5. Previously diagnosed with vitamin B12 deficiency and/or its related diseases. 10. Participant, at the investigator's discretion, is assessed to be unsuitable for the study, for reasons including but not limited to the presence of abnormal laboratory results, or clinical conditions; 11. Prior history of significant intolerance due to adverse reactions resulting from usage of amlodipine or other CCBs, valsartan or other ARBs, indapamide or other similar diuretics, metoprolol tartaric acid or other beta-blockers, or any drugs or health products containing folate or folic acid; 12. Regular consumption of folic acid or vitamin B compounds, or other compounds containing folic acid in the past 3 months; 13. The presence of any of the following conditions that could negatively influence a participant's ability to consent or participate in the trial: 1. Dementia; 2. Severe mental disorders; 3. Inability to express informed consent; 4. Unlikely to complete the study follow-up as specified by the protocol, or plans to relocate outside of the study area in the near future; 5. History of poor compliance when taking antihypertensive medications or is expected to have poor compliance during the study; 14. Refusal to participate, or inability to modify current drug regimen; 15. Women who are pregnant or breastfeeding; or subjects of childbearing potential who are unwilling or unable to use effective contraception during the study period. 16. Within one month prior to the first visit, having participated in any clinical trial for a drug that has not yet been officially approved by the state or is not currently approved for sale; or currently participating in any clinical trial that could potentially impact the results of this study (medication use, drug efficacy, drug interaction, etc.).
Conditions Glaucoma, Neovascular, Vascular Endothel...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

To prospect studying the efficacy and safety of treating NVG with the intracameral versus the intravitreal injection of Bevacizumab.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Procedure: Intracameral injection — A/C injection of 1.25 mg/0.05 mL bevacizumab
  • Procedure: Intravitreal injection — Vitreous injection of 1.25 mg/0.05 mL bevacizumab

Primary Outcomes

  • regression of nevolascularization (2 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2018-08-01
Completion: 2026-07-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Prince of Songkla University
Principal Investigators:
  • Assoc.Prof.Weerawat Kiddee, MD (PRINCIPAL_INVESTIGATOR) - Prince of Songkla University
Contact Information
Study Contact:
Assoc.Prof.Weerawat Kiddee, MD
+66874954626
kweerawat@hotmail.com
WEERAWAT KIDDEE, MD
66-81271-0644
kweerawat@hotmail.com
Glaucoma unit , Department of Ophthalmology Faculty of Medicine Prince of Songkla University
Interventions
  • Procedure: Intracameral injection — A/C injection of 1.25 mg/0.05 mL bevacizumab
  • Procedure: Intravitreal injection — Vitreous injection of 1.25 mg/0.05 mL bevacizumab
Study Locations (1 sites)
Glaucoma unit , Department of Ophthalmology Faculty of Medicine Prince of Songkla University, Hat Yai, Changwat Songkhla 90110 Thailand
Eligibility Criteria
Inclusion Criteria: 1. Diagnosis of neovascular glaucoma 2. The patients having IOP \> 21 mmHg, having the indication for trabeculectomy 3. The patients' age of at least 18-year-old 4. The patients having visual potential at least hand motion. 5. Present of NVI or NVA. 6. Willing and able to provide informed consent to participate in the study 7. Able to understand the purpose of the study, his/her role, and is available to return to the clinic/hospital for all required follow-up visits Exclusion Criteria: 1. One eye patient 2. Patients having severe corneal edema or total hyphema obscure NVI or NVA view. 3. Cannot obtain endothelial cell count. 4. History of bevacizumab or fluorescence dye allergy. 5. Active infectious ocular disease including endophthalmitis and corneal ulcer 6. History of systemic disease including ischemic heart disease, cerebrovascular disease, end-stage renal disease, liver failure, uncontrolled hypertension 7. Has or planning to be pregnant or breastfeeding

The "Global Paradise System" Registry

NCT05027685
Recruiting
Conditions Hypertension
Phase Not Applicable
Enrollment 3000
Locations 55 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

The GPS Registry is a multi-centre, single-arm, non-interventional (observational) registry. In addition to collecting data from patients treated as per standard clinical practice, the Registry will also regularly collect telemetric Home Blood Pressure (HBP) measurements and Patient Reported Outcome (PRO) data via a standardized quality of life questionnaire. The objective of the GPS Registry is to document the long-term safety and effectiveness of the commercially available Paradise Ultrasound Renal Denervation System when used per its labelling in patients deemed to be candidates for RDN as per physician's assessment.

Design

Study type: Observational Observational model: Case Only Time perspective: Other

Interventions / Regimen

  • Device: The Paradise Ultrasound Renal Denervation System — The CE-marked and commercially available ReCor Medical Paradise Ultrasound Renal Denervation System (Paradise System) is a catheter-based device designed to use ultrasound energy to thermally ablate the nerves surrounding the renal artery and serving the kidney.

Primary Outcomes

  • Incidence of all-cause mortality (Through 5 Years post-procedure)
  • Incidence of new onset end-stage renal disease (Through 5 Years post-procedure)
  • Significant decline in renal function (Through 5 Years post-procedure)
  • New renal artery stenosis (Through 5 Years post-procedure)
  • Incidence of renal artery perforation or dissection requiring an invasive intervention (Through 5 Years post-procedure)
  • Incidence of major vascular complications (e.g, clinically significant groin hematoma, arteriovenous fistula, pseudoaneurysm) requiring surgical repair, interventional procedure, thrombin injection, or blood transfusion as per site standard practice (Through 5 Years post-procedure)
  • Incidence of hospitalization for hypertensive crisis or symptomatic hypotension (Through 5 Years post-procedure)
  • Incidence of hospitalization for major cardiovascular- or hemodynamic-related events (e.g. HF; AF) (Through 5 Years post-procedure)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-01-13
Completion: 2031-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 3000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: ReCor Medical, Inc.
Principal Investigators:
  • Sofie Brouwers, Prof. (PRINCIPAL_INVESTIGATOR) - OLV Ziekenhuis Aalst Belgium
  • Felix Mahfoud, Prof. (PRINCIPAL_INVESTIGATOR) - Klinik für Kardiologie, Universitäres Herzzentrum Basel, Switzerland
Contact Information
Study Contact:
Helen Reeve-Stoffer, PhD
+44 (0) 794 774 8006
hreeve-stoffer@recormedical.com
Hajime Arnold
+1 650 912 9023
HArnold@recormedical.com
Thomas Weber, Dr.
Klinikum Wels-Grieskirchen GmbH
Interventions
  • Device: The Paradise Ultrasound Renal Denervation System — The CE-marked and commercially available ReCor Medical Paradise Ultrasound Renal Denervation System (Paradise System) is a catheter-based device designed to use ultrasound energy to thermally ablate the nerves surrounding the renal artery and serving the kidney.
Study Locations (55 sites)
Medical University of Vienna,, Vienna, 1090 Austria
Klinikum Wels-Grieskirchen GmbH, Wels, 4600 Austria
OLV Ziekenhuis Aalst, Aalst, Belgium
CHU Saint Pierre Brussels, Brussels, Belgium
UCL St Luc, Brussels, Belgium
Clinique CHS MontLégia, Liège, 4000 Belgium
CHU Grenoble Alpes - Hôpital Michallon, Grenoble, La Tronche 38700 France
CHU Bordeaux Hôpital St. André, Bordeaux, France
Assistance Publique Hôpitaux de Marseille (AP-HM), Marseille, 13354 France
HEGP (Hôpital Européen Georges Pompidouv) Paris, Paris, France
Eligibility Criteria
Inclusion Criteria: * Appropriately signed and dated informed consent * Age ≥18 at time of consent * Patient candidate for renal denervation with the Paradise System based on physician's assessment OR Patient treated with the Paradise Ultrasound Renal Denervation System within the 6 months prior to consent Exclusion Criteria: Patients who meet any of the contraindications listed in the Instructions for Use will be excluded. The contraindications are: * Stented renal artery * Less than 18 years of age * Pregnant * Known allergy to contrast medium * Renal arteries diameter \< 3 mm and \> 8 mm * Renal artery with Fibromuscular (FMD) disease * Renal artery aneurysm * Renal artery stenosis of any origin \>30% * Iliac/femoral artery stenosis precluding insertion of the Paradise catheter
Conditions Hypertension, Dyslipidemia
Phase PHASE1
Enrollment 36
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

A Randomized, Open-label, Two-arm, Two-period, Multiple-dose, Study to Evaluate Pharmacokinetic Drug-drug Interaction, Safety and Tolerability of UIC202601 and UIC202602 in Healthy Volunteers

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Investigational Product 1 — UIC202601 1Tab/day for 7 days
  • Drug: Investigational Product 2 — UIC202602 1Tab/day for 7 days
  • Drug: Investigational Product 1 + Investigational Product 2 — UIC202601+UIC202602 2Tab/day for 7 days

Primary Outcomes

  • AUCτ,ss (0 to 24hr)
  • Cmax,ss (0 to 24hr)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-07-01
Completion: 2026-09
Eligibility
Age: 19 Years – 54 Years
Sex: ALL
Volunteers: true
Enrollment: 36 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Korea United Pharm. Inc.
Contact Information
Study Contact:
Seongdae Kwon
031-467-9927
uro777@nate.com
Metro Hospital
Interventions
  • Drug: Investigational Product 1 — UIC202601 1Tab/day for 7 days
  • Drug: Investigational Product 2 — UIC202602 1Tab/day for 7 days
  • Drug: Investigational Product 1 + Investigational Product 2 — UIC202601+UIC202602 2Tab/day for 7 days
Study Locations (1 sites)
Metro Hospital, Anyang, Manan-gu 14096 South Korea
Eligibility Criteria
Inclusion Criteria: * Subjects aged 19 years or older and less than 55 years at the screening visit. * Subjects with a body weight of at least 50 kg (at least 45 kg for females) and a body mass index (BMI) of 18.0 kg/m² or higher and 30.0 kg/m² or lower at the screening visit. BMI (kg/m²) = Body weight (kg) / Height (m)² * Subjects who have no clinically significant congenital or chronic diseases and no pathological symptoms or findings based on medical examination at the screening visit. * Subjects determined to be eligible for participation in the clinical trial by the Investigator (or delegated Sub-investigator) based on the evaluation results of hematology, blood chemistry, serology, urinalysis, other clinical laboratory tests, physical examination, and electrocardiogram (ECG), which are established and performed according to the characteristics of the investigational product. * Subjects who agree that they and/or their spouse or partner will use highly effective contraception (excluding hormonal contraceptives) from the first administration of the investigational product until 14 days after the last administration to prevent pregnancy and who agree not to donate sperm or ova. * Highly effective methods of contraception: intrauterine device (IUD), bilateral tubal occlusion, vasectomized partner, sexual abstinence. * Subjects who have received and understood sufficient explanation regarding the purpose, procedures, characteristics of the investigational product, and anticipated adverse events of this clinical trial, and who have voluntarily signed the informed consent form. Exclusion Criteria: * Subjects with current or past history of clinically significant diseases involving the renal system (e.g., severe renal impairment), nervous system (e.g., cerebrovascular disease), immune system, respiratory system (e.g., bronchial asthma), urinary system, gastrointestinal system, endocrine system (e.g., congenital lipid metabolism disorders, severe diabetes mellitus), hematologic/oncologic system, cardiovascular system (e.g., severe hypertension, heart failure, coronary artery disease), reproductive system (e.g., endometrial hyperplasia, endometriosis), psychiatric disorders, or myopathy. * Subjects with a history of gastrointestinal surgery (except simple appendectomy or hernia repair) that may affect drug absorption, or with gastrointestinal disease. * Subjects with severe hepatic impairment, biliary obstruction, or cholestasis (this drug is excreted almost entirely via bile. Cholestasis, biliary obstructive disease, or hepatic impairment may be expected to reduce hepatic clearance.). * Subjects with active liver disease or persistent elevation of aminotransferase levels of unknown cause. * Subjects with hereditary angioedema or a history of angioedema during treatment with an ACE inhibitor or an angiotensin II receptor blocker. * Subjects who have taken enzyme-inducing or enzyme-inhibiting drugs such as barbiturates within 1 month before the first administration, or who have taken medications that may interfere with this clinical trial within 10 days before the first administration (however, participation may be allowed after considering pharmacokinetic and pharmacodynamic characteristics such as interactions with the investigational product and drug half-life). * Subjects who have consumed grapefruit-containing foods within 7 days before the first administration or who are unable to refrain from consuming such foods during the clinical trial. * Subjects who have participated in another clinical trial or bioequivalence study and received an investigational product within 6 months before the first administration. * Subjects who have donated whole blood within 8 weeks before the first administration, donated blood components within 2 weeks, or received a blood transfusion within 4 weeks. * Subjects considered unsuitable for participation based on screening assessments performed within 30 days before the first administration of the investigational product. * AST or ALT \> 1.5 × the upper limit of the normal range. * Total bilirubin \> 1.5 × the upper limit of the normal range. * eGFR (estimated Glomerular Filtration Rate), calculated using the MDRD (Modification of Diet in Renal Disease) equation, \< 60 mL/min/1.73m². * Positive results for serologic tests (hepatitis B, hepatitis C, human immunodeficiency virus \[HIV\], or syphilis). * After at least 5 minutes of rest, seated vital signs showing systolic blood pressure \> 139 mmHg or \< 100 mmHg, or diastolic blood pressure \> 90 mmHg or \< 60 mmHg. * Subjects who meet any of the following conditions within 1 month before the first administration. * Average alcohol consumption exceeding 21 drinks/week for males. * Average alcohol consumption exceeding 14 drinks/week for females. (1 drink = 50 mL of soju, 30 mL of spirits, or 250 mL of beer.) * Smoking more than 10 cigarettes per day on average. * Subjects who meet any of the following conditions. * Subjects with hypersensitivity to this drug or any of its components. * Subjects with hereditary problems of fructose or galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. * Subjects whom the Investigator (or delegated Sub-investigator) considers unsuitable for participation in this clinical trial for reasons other than the above inclusion/exclusion criteria (e.g., excessive tattoos). * Subjects with a history of drug abuse within 1 year before screening or those with a positive urine drug screening test. * Female subjects who are pregnant, suspected to be pregnant, or breastfeeding.
Conditions Hypertension, Hypertension, Systolic, Hy...
Phase NA
Enrollment 316
Locations 131 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

A prospective, multinational, randomized, double-blind, clinical trial evaluating the safety and effectiveness of a novel atrioventricular interval modulation (AVIM) algorithm downloaded into a dual-chamber Medtronic Astra/Azure pacemaker.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Device: Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated — Antihypertensive therapy utilizing atrioventricular interval modulation.
  • Device: Medtronic Astra/Azure DR MRI IPG with AVIM therapy Deactivated — AVIM therapy is deactivated

Primary Outcomes

  • Change from Baseline in the Mean 24-hour ambulatory systolic blood pressure (aSBP) at 3 Months (Baseline and 3 months post randomization)
  • Freedom from Unanticipated Serious Adverse Device Effects (USADE) (3 months post randomization)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-12-27
Completion: 2029-08
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 316 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Orchestra BioMed, Inc
Collaborators: Medtronic
Principal Investigators:
  • David Kandzari, MD (PRINCIPAL_INVESTIGATOR) - Piedmont Heart Institute
  • Andrea Russo, MD (PRINCIPAL_INVESTIGATOR) - Cooper University
Contact Information
Study Contact:
Steven J. Evans, MD
917-670-5933
sevans@orchestrabiomed.com
Angela Stagg
astagg@orchestrabiomed.com
Interventions
  • Device: Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated — Antihypertensive therapy utilizing atrioventricular interval modulation.
  • Device: Medtronic Astra/Azure DR MRI IPG with AVIM therapy Deactivated — AVIM therapy is deactivated
Study Locations (131 sites)
HonorHealth, Scottsdale, Arizona 85258 United States
Adventist Health Glendale, Glendale, California 91206 United States
Hoag Memorial Hospital Presbyterian, Newport Beach, California 92633 United States
Stanford, Redwood City, California 94063 United States
Scripps Clinic, San Diego, California 92121 United States
Sutter Valley Hospitals, San Francisco, California 94109 United States
South Denver Cardiology, Denver, Colorado 80210 United States
Colorado Heart and Vascular, Golden, Colorado 80401 United States
Intermountain Health Lutheran Hospital, Golden, Colorado 80401 United States
UCHealth Medical Center of the Rockies, Loveland, Colorado 80538 United States
Eligibility Criteria
Inclusion Criteria: 1. Patient has or is indicated for a dual-chamber pacemaker. Visit 1 can be performed within 30 days prior to a planned implant of a Medtronic Astra/Azure dual-chamber pacemaker system or at any time thereafter 2. On a stable antihypertension treatment regimen with at least 1 class of antihypertensive drug 3. Office SBP ≥135 mmHg and \<180 mmHg 4. Average 24-Hour aSBP ≥130 mmHg and \<170 mmHg Exclusion Criteria: 1. LVEF \<50% 2. NYHA Class III-IV 3. History of cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 6 months 4. Myocardial infarction (MI) within 3 months 5. Prior percutaneous or surgical coronary, carotid, or endovascular intervention within 3 months 6. Permanent atrial fibrillation 7. Mitral valve regurgitation greater than or equal to grade 3 8. Aortic stenosis with a valve area less than 1.5 cm2 9. Has an active or prior device-based anti-hypertensive treatment (e.g., renal denervation procedure, baroreflex activation therapy) 10. Has an existing active cardiac device or neurostimulator other than the recent Astra/Azure pacemaker implant
Conditions Primary Open Angle Glaucoma, Myopia
Phase Not Applicable
Enrollment 3000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

The overarching goal of our research study is to evaluate changes in visual function and optic nerve topography (the structure of the back of the eye) in patients with glaucoma (increased susceptibility to pressure inside the eye that can cause loss of vision) or those with an increased risk of developing the disease. The purpose of this study is to determine the best methods for detecting the presence or progression (worsening over time) of glaucoma in patients with and without myopia and its effects on daily and visual function and quality of life. With several sources of NIH and foundation funding over the last twenty years we have designed a robust research protocol to address the most challenging aspects of glaucoma management. The most recent focus of this research is 1) to improve our ability to detect open angle glaucoma in individuals with myopia and in individuals of European and African descent, 2) to determine whether monitoring of the retinal vasculature with new optical imaging instruments can improve glaucoma management and elucidate the pathophysiology of the disease, and 3) to differentiate between age-related changes and glaucomatous progression. The grants supporting this project include 3 NIH funded studies, 1) the University of California, San Diego UCSD -based "Diagnostic Innovations in Glaucoma Study" (DIGS funded since 1995): 2) the "African Descent and Glaucoma Evaluation Study" (ADAGES funded since 2002), 3) the Brightfocus Foundation National Glaucoma Research Program and 4) the UCSD-based "Diagnosis and Monitoring of Glaucoma with Optical Coherence Tomography Angiography" (funded since 2018). The ADAGES is a multi-center study with data collection also conducted at 2 other academic sites, the University of Alabama at Birmingham, and Columbia University. Enrolled healthy participants, glaucoma suspects and glaucoma patients are generally asked to return for two or more visits a year for several years. We then analyze whether the glaucoma patients are progressing and what factors influence their glaucoma status compared to healthy subjects and individuals suspected of having glaucoma.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 1995-04
Completion: 2030-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 3000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, San Diego
Collaborators: National Eye Institute (NEI)
Principal Investigators:
  • Linda Zangwill, PhD (PRINCIPAL_INVESTIGATOR) - University of California, San Diego
Contact Information
Study Contact:
Veronica Inpirom
858-822-4669
vrubio@health.ucsd.edu
Veronica Inpirom
858-822-4669
vrubio@health.ucsd.edu
UCSD, Hamilton Glaucoma Center
Linda M Zangwill, PhD
UCSD, Hamilton Glaucoma Center
Interventions
N/A
Study Locations (1 sites)
UCSD, Hamilton Glaucoma Center, La Jolla, California 92093-0946 United States
Eligibility Criteria
Inclusion: * Subjects are healthy controls with or without myopia, and patients with or without myopia with a diagnosis of glaucoma, glaucoma suspect and ocular hypertension * They will be considered if they are above 18 years old. * There is no upper age limit * Subject are not restricted by gender, race or ethnicity. Exclusion: -Participants with other ocular or systemic conditions and treatment, which may affect visual function, are excluded.

The Preeclampsia Registry

NCT06377878
Recruiting
Conditions Preeclampsia, Eclampsia, HELLP Syndrome,...
Phase Not Applicable
Enrollment 20000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of The Preeclampsia Registry is to collect and store medical and other information from women who have been medically diagnosed with preeclampsia or a related hypertensive (high blood pressure) disorder of pregnancy such as eclampsia or HELLP syndrome, their family members, and women who have not had preeclampsia to serve as controls. Information from participants will be used for medical research to try to understand why preeclampsia occurs, how to predict it better, and to develop experimental clinical trials of new treatments. The Registry will consist of a web-based survey and mechanism for collecting and reviewing medical records. This data will be utilized for immediate investigator-driven cross-sectional research projects (after proposal review by the Registry's scientific advisory board and as directed by the PI). Participants may also choose to be contacted regarding possible participation in future studies, about providing a biospecimen, as well as investigator-driven clinical trials. The Registry is anticipated to exist long-term and to serve as a foundation of participants from which to draw for studies of preeclampsia, anticipated to evolve as our scientific understanding of preeclampsia evolves.

Design

Study type: Observational Observational model: Case Control Time perspective: Other

Primary Outcomes

  • Self Reported Diagnosis of Preeclampsia and Hypertensive Disorders of Pregnancy Confirmed by Medical Records (Will be assessed yearly, up to 20 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2013-09-01
Completion: 2040-05
Eligibility
Age: 13 Years and older
Sex: ALL
Volunteers: true
Enrollment: 20000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Preeclampsia Foundation
Principal Investigators:
  • Eleni Z Tsigas, BA (PRINCIPAL_INVESTIGATOR) - Preeclampsia Foundation
Contact Information
Study Contact:
VeeAnn Argyle
321-421-6957
Registry@preeclampsia.org
Eleni Z Tsigas, BA
321-421-6957
VeeAnn Argyle
321-421-6957
Registry@preeclampsia.org
Preeclampsia Foundation
Interventions
N/A
Study Locations (1 sites)
Preeclampsia Foundation, Melbourne, Florida 32940 United States
Eligibility Criteria
Inclusion Criteria: * Women who were medically diagnosed with preeclampsia or a related hypertensive disorder of pregnancy (HDP) such as eclampsia or HELLP syndrome. * Female or Male relatives of affected women * Women who have never had preeclampsia or hypertensive disorders of pregnancy, but who would like to serve as "controls" in research studies of preeclampsia. * An authorized representative may complete the questionnaire and provide consent for a woman who had preeclampsia, but has died or is disabled as a result. Exclusion Criteria: * Those unable to provide consent * Prisoners * Individuals unable to speak English
Conditions Salt-Sensitivity of Blood Pressure
Phase PHASE4
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

The overall objective of this project is to identify the key salt-sensing regions of the brain and determine the underlying mechanism of sodium sensing. The investigators will assess how the brain responds to an acute increase of salt in the blood using MRI. This will be done during a 30-minute infusion of a saline solution containing 3% salt. One trial will be conducted with a salt sensing channel blocker and one trial without the salt sensing channel blocker. This will help to assess the role of a specific salt sensing channel in the brain. Salt sensitivity of BP will be assessed using 7-day dietary feeding where participants will be given food to consume for 7-days. Comparisons will be made between salt resistant (no change in blood pressure going from low to high salt diets) and salt sensitive adults (a change in blood pressure going from low to high salt diets). The investigators think the changes in MRI will be greater in salt sensitive compared to salt resistant subjects.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: Double

Interventions / Regimen

  • Drug: Furosemide (Diuretic) — The diuretic furosemide will be given during a 3% hypertonic saline infusion to examine blockade of the NKCC2.
  • Other: Hypertonic Saline Infusion — 3% Hypertonic saline infusion to acutely increase sodium and osmolality

Primary Outcomes

  • Bold fMRI (1 hour)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2024-03-05
Completion: 2028-07-01
Eligibility
Age: 40 Years – 60 Years
Sex: ALL
Volunteers: true
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Delaware
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Contact Information
Study Contact:
Megan Wenner, PhD
3028317343
mwenner@udel.edu
Virginia Nuckols, PhD
gnuckols@udel.edu
Ginny Nuckols, PhD
gnuckols@udel.edu
University of Delaware
Interventions
  • Drug: Furosemide (Diuretic) — The diuretic furosemide will be given during a 3% hypertonic saline infusion to examine blockade of the NKCC2.
  • Other: Hypertonic Saline Infusion — 3% Hypertonic saline infusion to acutely increase sodium and osmolality
Study Locations (1 sites)
University of Delaware, Newark, Delaware 19713 United States
Eligibility Criteria
Inclusion Criteria: * Age: \> 40 years or \< 60 years * Blood pressure: \> 100/60 mmHg or \< 140/90 mmHg * BMI: \> 18.5 kg/m2 or \< 35 kg/m2 * Serum potassium: \> 3.5 mmol/L or \< 5.5 mmol/L * No history of cardiovascular, renal, metabolic, or neurological disease Exclusion Criteria: * Age: \< 40 years or \> 60 years * Blood pressure: \< 100/60 mmHg or \> 140/90 mmHg * BMI: \< 18.5 kg/m2 or \> 30 kg/m2 * Serum potassium: \< 3.5 mmol/L or \> 5.5 mmol/L * Abnormal ECG * History of - cardiovascular, cancer, metabolic, respiratory, renal disease * Hormone replacement therapy * Current tobacco or nicotine use * Pregnant or nursing mothers * Major brain injury (concussions do not count) * Clinically diagnosed psychiatric or neurological disorder * Clinically diagnosed anxiety or depression * Psychiatric, neurological, anxiety or depression medications * Hypertension medications * Sulfonamide drug allergy * Contra-indications to MRI (implants, metal, etc) * Claustrophobia